Sonnet’s proprietary FHAB™ (Fully Human Albumin Binding) technology enables the development of innovative targeted biologic drugs with enhanced single- or bi-specific mechanisms.

Biotechnology

Sonnet BioTherapeutics

Pankaj Mohan

Kal Ghosh

Stephen J. McAndrew

Richard Kenney

Susan Dexter

John K. Cini

Jay Cross

The Advisory Team at Sonnet BioTherapeutics provides strategic guidance and expert insights to support the development and advancement of biologic drugs using the company's proprietary FHAB™ technology. Their collective expertise ensures that the company's innovative therapies achieve clinical and commercial success.

Advisory Team

Directors

Leadership Team

Advisory Team

About

Team members

Other teams at Sonnet BioTherapeutics

Directors

Leadership Team